Eric Pennock, MD
Pediatric Ophthalmology and Strabismus Specialist · Cranberry Twp, PANPI 1760669949
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,000 of the $3,110 with a category attached, or 96.5%. Amgen accounts for 97.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $3,000 and has fallen 98.2% since, to $55 in 2025.
Across 6 payments — averaging $518.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Coopervision Inc.$47
- ANI Pharmaceuticals, Inc.$23
- Spark Therapeutics, Inc.$18
Across 10 payments — averaging $11,335 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch & Lomb Americas Inc.$113K
What the payments were for
- Speaking & faculty fees$3,00096%
- Food & beverage$1104%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 2 | $3,022 |
| Coopervision Inc. | 2 | $47 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Spark Therapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$3,000
How this compares
Too few pediatric ophthalmology and strabismus specialist providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 23 | $229 |
Paid to pharmacies, not to this prescriber.
Other pediatric ophthalmology and strabismus specialist in Cranberry Twp
- Jane HughesCranberry Twp$39
- Amanda ElyHershey$5K
- Judith LavrichPhiladelphia$5K
- Danielle SarloPhiladelphia$477
- Christianne SchoedelGettysburg$439
- Marjan Imani FooladiPittsburgh$219
- Preeti PatilPittsburgh$177
- Lee KlombersLancaster$107
- Meghal GagraniPittsburgh$99
- Farid KalantaritarariPittsburgh$75
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.